Monopar Therapeutics (NASDAQ:MNPR) reported positive topline results from its Phase 3 FoCus study, marking a significant milestone in the development of ALXN1840 for patients with Wilson disease.
The data revealed that the investigational treatment produced superior neurological improvement and lower rates of clinical worsening compared to the existing standard of care (SoC) through 48 weeks of treatment.
Wilson disease is a rare genetic disorder that causes toxic copper accumulation in the body, often leading to severe neurological and hepatic impairment.
In the trial, patients treated with ALXN1840 demonstrated a stark difference in disease progression; only 9% of the ALXN1840 cohort experienced clinically meaningful worsening, compared to 25% of those receiving standard of care.
This result was statistically significant with a p-value of 0.038.
Beyond preventing deterioration, ALXN1840 showed a robust ability to reverse symptoms.
Improvement rates for patients on the Monopar therapy reached 45%, outpacing the 32% recorded for the standard of care group.
Follow-up data further suggested that these therapeutic benefits are durable, with clinical gains sustained over a period of approximately three years.
The success of the FoCus trial provides a clear regulatory path for the company.
Monopar confirmed that it is currently finalizing the necessary documentation to support a New Drug Application (NDA) for ALXN1840, which it expects to submit to the U.S. Food and Drug Administration in mid-2026.